RVPH — Reviva Pharmaceuticals Holdings Share News
0.000.00%
Last trade - 00:00Brief: Reviva Pharmaceuticals Q2 EPS USD -0.26
Reviva Pharmaceuticals Holdings, Inc. expected to post a loss of 29 cents a share - Earnings Preview
Brief: Reviva Announces Grant Of European Patent Covering Use Of Brilaroxazine For The Treatment Of Pulmonary Hypertension
Brief: Reviva Announces Closing Of $3 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
U.S. RESEARCH ROUNDUP-AN2 Therapeutics, Ecolab, RPM International
Brief: Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia
Reviva Pharmaceuticals Holdings, Inc. reports results for the quarter ended in March - Earnings Summary
Brief: Reviva Pharmaceuticals Q1 EPS USD -0.25
Brief: Reviva Announces FDA Alignment On Brilaroxazine Clinical Trials For NDA In Schizophrenia
Brief: Reviva Pharmaceuticals Previous Financial Statements For FY 2022, Interim Financial Statements Quarter Ended Sept 30, 2022, No Longer Be Relied Upon
Brief: Reviva Pharmaceuticals Holdings Inc Files Non-Timely 10-K With The U.S. SEC- SEC Filing
Reviva Pharmaceuticals Holdings, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Brief: Reviva Pharmaceuticals Holdings Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing
U.S. STOCKS ON THE MOVE-SeaStar, SJW Group, Pinterest
U.S. STOCKS ON THE MOVE-Crypto, Miromatrix Medical, US banks
U.S. STOCKS ON THE MOVE-JinkoSolar, Reviva, MeiraGTx
Reviva soars on success of schizophrenia drug in late-stage trial
Reviva Pharma's schizophrenia drug succeeds in late-stage study (updated)
Reviva Pharma's schizophrenia drug succeeds in late-stage study